New hope for brain metastases: Dual-Drug attack on HER2 breast cancer

NCT ID NCT07152782

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (a targeted antibody-drug conjugate) and neratinib (a targeted pill that blocks HER family signals)
What this could lead to: If successful, this could provide a new, more effective treatment option for people with HER2-positive breast cancer that has spread to the brain, potentially improving how long the cancer stays under control.
What could go wrong: This is a Phase II trial, so it is still early. The combination may not work better than the standard drug alone, or side effects could be more severe. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER WITH BRAIN METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER WITH BRAIN METASTASIS HER2-POSITIVE BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.